Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crisugabalin in Patients With Herpes Zoster
NCT07307976Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Dec 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of crisugabalin besilate in herpes zoster (HZ) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Numeric Rating Scale at 7 days. Started Dec 2025; status: recruiting.
02
Drugs
crisugabalin besilate
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07307976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07307976.